We found that knockdown of FANCG, FANCE, FANCD2, and BRCA1 significantly sensitized HL60 AML cells to volasertib with varying degrees of severity (Fig. 3B–E). The gene discussed is BRCA1; the disease is acute myeloid leukemia.